ReviewVirusdisease2022
A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges.
Review in Virusdisease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A systematic review of methods used for COVID-19 telehealth systems evaluation: lessons from past experiences for future use.BMC health services research · 2025Pooled it
- A Systematic Review of Ocular Complications Following Different Types of Covid-19 Vaccines.Journal of immunology research · 2025Pooled it
- Effectiveness and safety of COVID-19 vaccines on maternal and perinatal outcomes: a systematic review and meta-analysis.BMJ global health · 2024Pooled it
- Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.Signal transduction and targeted therapy · 2022Trial
- Attitudes and Behaviors of Canadians Towards COVID-19 Prevention Measures According to Vaccination Status: A Multi-phase, Cross-sectional Sequential Observational Cohort Study from May 2021 to June 2022.International journal of behavioral medicine · 2026Article
- Targeting peptidyl-arginine deiminase 4 suppresses SARS-CoV-2 replication and modulates the inflammatory response.iScience · 2026Article
- SARS-CoV-2 nucleocapsid protein-specific monoclonal antibodies as tools for studying its antigenic structure and interaction with host cells.Scientific reports · 2026Article
- COVID-19 Infection vs Vaccination and the Risk of New-onset Psoriasis.Acta dermato-venereologica · 2026Article
- Assessing SARS-CoV-2 vaccine effectiveness in health workers: a cohort study conducted during the pandemic decline phase in five hospitals, affiliated to Al-Azhar University- Egypt.BMC infectious diseases · 2025Article
- Development and in vivo evaluation of a SARS-CoV-2 inactivated vaccine using high hydrostatic pressure.NPJ vaccines · 2025Article
- Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern.Vaccines · 2025Review
- Cardiovascular Sequelae of the COVID-19 Vaccines.Cureus · 2025Review
- The ZNF717-rs2918520 genotype contributes to COVID-19 severity: a Taiwanese cohort study.BMC infectious diseases · 2025Article
- Replication-incompetent VSV-based vaccine elicits protective responses against SARS-CoV-2 and influenza virus.Science advances · 2025Article
- Vaccination Coverage Covid-19 and Self-Reported Adverse Post-Vaccination Events in Mbuji-Mayi, DR Congo.Infection and drug resistance · 2025Article
- COVID-19 vaccination patterns among oral cancer patients: A comprehensive analysis in a medical center in Taiwan.Journal of dental sciences · 2025Article
- Antigenic Imprinting Dominates Humoral Responses to New Variants of SARS-CoV-2 in a Hamster Model of COVID-19.Microorganisms · 2024Article
- The Impact of HIV on B Cell Compartment and Its Implications for COVID-19 Vaccinations in People with HIV.Vaccines · 2024Review
- AI Promoted Virtual Screening, Structure-Based Hit Optimization, and Synthesis of Novel COVID-19 S-RBD Domain Inhibitors.Journal of chemical information and modeling · 2024Article
- Reported Adverse Events and Associated Factors in Korean Coronavirus Disease 2019 Vaccinations.Journal of Korean medical science · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present SARS-CoV-2 induced COVID-19 pandemic is responsible for millions of deaths, illnesses, and economic loss worldwide. There are 21 COVID-19 vaccines from different platforms approved worldwide for emergency use until 13 August 2021. Later, BNT162b2 obtained full approval from the FDA. The efficacy of the leading vaccines such as BNT162b2, mRNA-1273, Gam-Covid-Vac, Ad26.COV2.S, ChAdOx1 nCoV-19, and BBIBP-CorV, against SARS-CoV-2 documented as 95%, 94.1%, 91.6%, 67%, 70.4%, and 78.1%, respectively. Moreover, against the Delta variant of SARS-CoV-2, BNT162b2, ChAdOx1 nCoV-19, and BBV152 showed 88%, 70%, and 65.2% efficacy, respectively. Apart from the common adverse effects such as fever, fatigue, headache, and pain in the injection site, Bell's palsy with BNT162b2, myocarditis and pericarditis with mRNA-1273, and thrombosis with ChAdOx1 nCoV-19 have been reported though seemed not alarming. Furthermore, global production and distribution of vaccines should be ensured in an equal and justifiable way that the immunity and protection against the virus would be optimum and persistent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.